Curasight

About Us

Curasight is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology provides improved diagnosis and treatment in multiple cancer types, most notably for brain and prostate cancer.

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Curasight A/S Achieves First Milestone under collaboration with Curium Inc.

Mon, Jan 22, 2024 07:00 CET

· USD 500.000 payment is the first milestone under the global license and collaboration agreement for the development and commercialization of uTRACE[®] for use in prostate cancer between Curasight A/S and Curium Inc. · Milestone relates to the validation of GMP manufacturing of finished product and illustrates progress in the development plan for uTRACE[®] PET imaging technology · Under the agreement signed in 2023 Curasight is eligible to receive up to mUSD 70 in development milestones plus additional commercial milestones and double-digit royalties on sales upon commercialization

There are no items matching the current filter

There are no more items matching the current filter

Back to top

Share

About Us

Curasight A/S Achieves First Milestone under collaboration with Curium Inc.

Subscribe